Clemson University

TigerPrints
All Theses

12-2015

DECELLULARIZED BOVINE NUCLEUS
PULPOSUS AS A BIOMIMETIC SCAFFOLD
FOR INTERVERTEBRAL DISC
REGENERATION
Christopher Fernandez
Clemson University, cfern141@gmail.com

Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
Fernandez, Christopher, "DECELLULARIZED BOVINE NUCLEUS PULPOSUS AS A BIOMIMETIC SCAFFOLD FOR
INTERVERTEBRAL DISC REGENERATION" (2015). All Theses. 2257.
https://tigerprints.clemson.edu/all_theses/2257

This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

Theses

DECELLULARIZED BOVINE NUCLEUS PULPOSUS AS A BIOMIMETIC
SCAFFOLD FOR INTERVERTEBRAL DISC REGENERATION
A Thesis
Presented to
the Graduate School of
Clemson University
In Partial Fulfillment
of the Requirements for the Degree
Master of Science
Bioengineering
by
Christopher Fernandez
December 2015
Accepted by:
Dr. Jeremy Mercui, Committee Chair
Dr. Dan Simionescu
Dr. Sonny Gill

ABSTRACT
Low back pain (LBP) is a significant burden with a lifetime prevalence of 84%
and estimated expenditures of $85.9 billion.1,2 Although LBP is multifactorial; it has been
shown that LBP can originate from degenerating intervertebral discs (IVDs); a process
which initiates in the nucleus pulposus (NP); a hydrated tissue primarily composed of
type 2 collagen and proteoglycan. Current therapies for IVD degeneration (IDD) are
palliative and merely delay surgical management. While these procedures may relieve
pain temporarily, they fail to address the underlying cause of degeneration and make no
attempt to regenerate the effected tissue. Additional concerns with the use of these
treatments include the potential for accelerating degeneration in adjacent IVDs and that
they are surgical strategies typically employed only during the late stages of IDD
progression.3–5
The purpose of this research was to develop a decellularization procedure to
create a biomimetic NP scaffold for use in the early-stages of IDD, which may assist in
mitigating, halting or reversing the progression of degeneration. The objectives of this
research were to: (1) develop a procedure to decellularize healthy bovine caudal NPs to
eliminate xenogeneic cellular remnants while retaining type 2 collagen and
glycosaminoglycan content, (2) evaluate the resultant scaffolds mechanical properties,
and (3) evaluate the cytocompatiblity of the scaffold with human amniotic membrane
derived mesenchymal stem cells (hAMSCs).
Results illustrate our ability to remove greater than 93% of bovine DNA (with no
residual base-pairs present). Concomitantly, greater than 200µg of glycosaminoglycan
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(GAG) per milligram of sample dry weight was maintained. Furthermore measurement of
hydroxyproline (HYP) content within NP scaffolds demonstrated a GAG:HYP ratio of
15:1, which is comparable to values reported for healthy human NP6. Histological and
macroscopic evaluations of the scaffold illustrate a GAG-rich matrix, which closely
resembles the human NP and no presence of cells within the scaffold, thus the scaffold
was referred to as an acellular bovine NP (ABNP) scaffold. Mechanical evaluations of
this ABNP scaffold yielded viscoelastic properties similar to a healthy human native
NP.7–9 Lastly, evaluation of the cytocompatibility has been performed and has proven the
ability of the ABNP scaffold to maintain cell viability at 95% up to fourteen days. The
results of this research indicate a promising scaffold for further analysis for the treatment
of IDD.
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CHAPTER ONE
LITERATURE REVIEW
1.1 The Clinical Significance of Intervertebral Disc Degeneration
Low back pain (LBP) is a significant burden with a lifetime prevalence of 84%
and estimated expenditures of $85.9 billion.1,2 Although LBP is multifactorial; it has been
shown that LBP can originate from degenerating intervertebral discs (IVDs); a process
which initiates in the nucleus pulposus (NP); a hydrated tissue primarily composed of
type 2 collagen and the proteoglycan aggrecan. Current therapies for IVD degeneration
(IDD) are palliative and merely delay surgical management. While these procedures may
relieve pain temporarily, they fail to address the underlying cause of degeneration and
make no attempt to regenerate the effected tissue. Additional concerns with the use of
existing treatments, spinal fusion and total disc arthroplasty, include the potential for
accelerating degeneration in adjacent IVDs and that they are surgical strategies typically
employed only during the late stages of IDD progression.3–5

1.2 The Gross Structure of the Nucleus Pulposus
1.2.1

Biochemical Components of the Nucleus Pulposus
The organization and composition of the NP is what defines its ability to perform

in its specific physiological environment. A combination of collagen, proteoglycans,
cells, MMPs, ADAMTS, & TIMPs combine in specific ratios not seen anywhere else in
the body except in this specific environment. When the ratio of proteoglycans to collagen
starts to fall and the cells begin to die the environment of the NP begins to change and
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degrade in one of the most vicious cycles of degradation observed in the body. Without
all of the components working synergistically the entire IVD will fail starting within the
NP. In these situations the mechanical properties of the IVD degrade and are unable to
support spinal loads. The major biochemical components of the NP are as follows:
collagen, proteogycans, namely aggrecan, cells, and products of cells. These major
components of the NP are responsible for defining the nature of the environment and all
aid in supporting the mechanical loads demanded of the body.

1.2.1.1 Proteoglycans
Aggrecan is the largest component of the NP by dry weight, comprising
approximately 50% of the tissue.5,10 Aggrecan is a proteoglycan known for its ability to
retain water, which is necessary in the dynamic compression cycles the NP undergoes
daily. It is comprised of a core protein backbone with link proteins that enable
attatchment of aggrecan to a hylaronic acid backbone. Chondroiton sulfate (CS) and
keratin sulfate (KS) (Figure 1.1) are also attached to the aggrecan protein giving the
molecule its characteristic “bottle brush” architecture and fixed charge density.
Furthermore aggrecan is comprised of three globular regions termed G1, G2, and G3,
with a short interglobular domain (IGD) which separates G1 from G2, and a long GAGattachment region separating G2 from G3.11 The G1 region is responsible for interacting
with the HA, connecting the two backbones together. The region between G2 and G3 can
be split up into three regions known as KS, CS1, and CS2 where the GAGs are rich
giving aggrecan its aggregating properties.11 Due to the numerous GAG chains aggrecan
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provides the NP with osmotic properties that allow the structure swell and withstand
compression. Specific to the NP the GAG to hydroxyproline (HYP) ratio is 27:1 whereas
elsewhere cartilage throughout the body is closer to a 2:1 ratio.6,12 Also, due to this high
concentration of aggrecan it has been shown that is also functions to impede angiogenesis
and neurogenesis inside the NP.11,13,14 As aggrecan degenerates from use and age the
onset of IDD begins. Aggrecan is cleaved at two notable regions causing the aggregates
to be free floating and unable to retain water properly under compressive loads. These
two sites for aggrecanases to cleave are the IGD and CS2 regions.11,15 The main
aggrecanases, that will be discussed later, are MMP-3, 7, and 12 and ADAMTS-1, 4, 5, 8,
and 15.11,15–17 These aggrecanases are found naturally in the NP tissue and are thought to
be part of the normal tissue tunrnover for aggrecan however with age and other factors
the rate of catabolism is much faster than the rate of anabolism of aggrecan therefore
degeneration and breakdown of aggrecan occurs. This shift in aggrecan to collagen ratio
begins a vicious cycle of breakdown and inflammation of NP tissue. Other proteoglycans
present in the NP tissue are decorin, biglycan, fibimodulin and lumican, however their
role is till unknown and remains to be a minor factor compared to aggrecan’s role in the
NP.18 Aggrecan is a critical component for any attempts for tissue regeneration of the NP.
This is because it is understandably difficult in order to artificially create aggrecan,
therefore aggrecan either needs to be maintained in scaffold creation via a
decellularization procedure or produced in large quantities by healthy NP-like cells.
Therefore, any development of NP tissue replacements there is a critical need to provide
large quantities of relative GAG content to not only condition any stem cells seeded on
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the scaffold but to also maintain the critical biochemical and biomechanical properties
needed for a functional NP replacement.

Figure 1.1 Domain structure of aggrecan.11

1.2.1.2 Collagen
Collagen, primarily collagen type II, forms about 20-25%, or ~15µg HYP/mg
tissue dry weight, of the NP dry weight tissue.5,10 Collagen type II forms a loose network
with other collagens, type IX and XI, found within the NP to form cross-bridges between
collagen type II molecules and other ECM components. Together they form a ECM
matrix specialized in providing resistance to swelling (Figure 1.2).19,20
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Figure 1.2: Depiction of the function of proteoglycans and collagen fibers within the NP21

1.2.1.3 Cells
Two different populations of cells are found to inhabit the NP. First are
chondrocyte-like cells, known as NP cells, which have an approximate density of 4x106
cells/cm3. These cells reside within lacunae and appear oval or rounded in shape.22,23
These cells are responsible for producing all the ECM components and degradative
enzymes and maintaining the GAG: HYP. The second population of cells present within
the NP is known as notochordal cells, which are highly vacuolated and populate the NP at
birth but disappear by the age of 4-10 years in humans.24,25 The purpose of these is still
unclear at this time.
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1.2.2

Mechanical Properties of the Nucleus Pulposus
The mechanical properties of the human NP are the definition of its biochemical

properties. The properties of the human NP have been reported using a multitude of
different types of mechanical testing, such as unconfined and confined compression using
incremental strains for stress relaxation analysis.9,26 Data from unconfined compression
defines the equilibrium modulus as 5.39 ±2.56 kPa, a Poisson’s ratio of 0.62 ± 0.15 at
high strains and a Poisson’s ratio of 0.125 at low strains, and a percent relaxation of
65.77 ± 11.3%.8,26 Utilizing confined compression it is possible to calculate the aggregate
modulus, stiffness at zero flow, and permeability, resistance to fluid flow. The values of
these of healthy human NP are 1.01 ± 0.43MPa and 0.9 ± 0.43 10-15 m4/N-s.27 Under
dynamic testing conditions the NP behaves similarly to a solid since the storage modulus
is always greater than the loss modulus no matter what frequency is tested. The phase
angle (δ, the lag between stress and stain) of the human NP ranges from 15-27˚ over a
testing frequency of 0.01-2 Hz indicating a viscoelastic response.9 The complex shear
modulus, G*, ranges for the human NP between 7-21kPa.7

1.3 Intervertebral Disc Degeneration
IVD degeneration (IDD) is a cell-mediated process driven by several factors
including genetics, injury, mechanical forces, and disc nutrition. The combination of the
factors culminates in destructive changes to the NPs ECM. There is ultimately an
imbalance of tissue production and destruction causing the natural ECM within the disc
to change, therefore changing the mechanical properties of the NP. These structural
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changes to the NP have four different grades ranging from mild degeneration to severe
(Figure 1.3).

Figure 1.3 Depiction of the different grades of IDD28

1.3.1

Changes within the NP
The overall changes being observed in degeneration of the NP s the imbalance of

ECM turnover, matrix anabolism is not keeping pace with matrix catabolism.29
Additionally, the production of proteases such as, matrix metalloproteinases (MMPs) and
a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) without the
production of tissue inhibitor of metalloproteinases (TIMPs) will cause an imbalance of
matrix production. During this degeneration aggrecan and water content both decrease as
well as the production of new proteoglycans decrease. This alteration further adds to the

7

degeneration of the NP. Increased fragmentation of aggrecan ultimately leads to reduced
osmotic pressure within the NP causing a destabilization.11
Cells are viewed as the primary reason for this degeneration for the NP due to
their increased production of MMPs.29 These MMPs lead to the destruction and cleavage
of aggrecan within the NP causing more significant changes to the structure of the NP.
Without high amounts of intact aggrecan present within the NP it has been demonstrated
that blood vessels and neural ingrowth can occur further destabilizing the NP as well as
causing increased pain.13,14
Due to biochemical changes in the NP the mechanical properties also change. The
NP is unable to maintain the loading it was once capable of due to the loss of the osmotic
pressure created by aggrecan. With the degeneration of the NP there a significantly
increased shear modulus and effective aggregate modulus.4,27 These altered properties in
turn cause a lost of disc height which in turn can pinch nerves in the spinal column
further increasing pain.

1.4 Current Treatments for IDD and Nucleus Pulposus Replacement
Current surgical options are palliative and only treat the symptoms and not the
cause of IDD. Additionally, surgical means affect the adjacent IVDs by changing the
mechanics of the spinal functional unit further aiding to IDD. Present surgical options,
total disc arthroplasty and spinal fusion, have been proven to help aid in relieving pain in
the patient for a time but it is also known that the adjacent discs begin the process of
degeneration due to the altered biomechanics in the region. The adjacent discs experience
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greater pressure and are unable to move as freely as they were pre-surgical intervention
and may require a second surgery to fix and eliminate pain again.30–36 Therefore it is
imperative to find a treatment that attempts to mitigate or halt the progression of IDD in
order to preserve the surrounding IVDs.

1.5 Current Tissue Engineering Approaches to IDD
1.5.1

Stem Cell Models
For most tissue engineering approaches there a suitable cell source is critical and

must be identified. A cell source is typically needed because there are dramatic
reductions in viable cell numbers within degenerated tissue and the remaining cells may
exhibit increased senescence and altered phenotype, this includes cells native to the NP.37
Additionally, autologous NP cells are not a viable option for several factors: 1) NP cells
are sparse and would therefore not provide adequate quantity for a primary cell culture,
2) harvesting NP cells from adjacent healthy discs would cause degeneration from the
IVDs harvested, 3) harvesting cells from the degenerated disc would only accelerate
degeneration, 4) NP cells from degenerated disc, as discussed prior, exhibit altered
phenotype, increased senescence, increased expression of degradative enzymes as well as
limited capacity for matrix production.37–39 Therefore there is a need to find an alternative
source of cells for regenerating the NP.
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1.5.2

Utilization of Scaffolds
The utilization of biomaterials has been heavily researched as an alternative

treatment for IDD. While it has been shown that there are many stem cell sources may
have a positive effect in treating IDD. It is evident that there needs to be a suitable
scaffold material capable of supporting the survival of the stem cells. The environment of
a degenerated disc is rich in degradative enzymes and proteases, which could cause issues
for an implanted material.40,41 Therefore it may be beneficial to remove the degraded
portions of the NP. This however, creates a void where a biomaterial will fill providing
restorative factors to the NP. The scaffolds would therefore need to provide not only
restorative factors but also provide mechanical support. An ideal scaffold would protect
cells, support differentiation of cell sources into NP-like cells, provide mechanical
support, and degrade into non-cytotoxic components. To date, scaffolds developed are
unable to closely mimic the biochemical or mechanical properties of the healthy human
NP.42–45

1.5.2.1 Natural Scaffolds for NP Regeneration
The use of natural biomaterials for tissue engineering purposes is due to the innate
properties of the material to have good biocompatibility and low immunogenicity in the
native environment. However, other properties such as mechanical properties and
degradation rate/products must also be compliant with the tissue because it is still
possible for an immune response to occur. With this in mind a couple of groups have
explored the possibility of using fibroin as a biomaterial for a NP scaffold replacement.

10

Silk fibroin has been chosen for research as an NP replacement due to high similarity in
terms of biochemical composition.46
Current studies utilizing silk fibroin process the material using freeze-drying
paraffin-sphere-leaching in order to create pores within the scaffold (Figure 1.4).46,47
Scaffolds were then examined for cell viability and mechanical properties. From initial
studies Zeng proved cells were able to not only survive but were able to proliferate on the
construct. They also depicted significant increases in proteoglycan, collagen type II, and
compressive elastic modulus of their cell seeded scaffolds out to three weeks culture
time.46 However, even though proteoglycan content had significantly increased, it had
only increased to ~50ng/mL this is orders of magnitudes lower than what is present in
healthy native NP, ~200-400µg/mg48, as well as the GAG: HYP ratio was approximately
2: 1 throughout the experiment which is more similar to cartilage throughout the body but
not in the NP where the ratio is 27: 1 GAG: HYP. 6,46

Figure 1.4: Example procedure of forming a silk fibroin scaffold.47

11

1.5.2.2 Injectable Scaffolds for NP Regeneration
Due to ease of procedure the investigation of using an injectable hydrogel has
been heavily researched. The uses of alginate and collagen-hyaluronic acid (HA)
scaffolds have been of interest to several groups. Alginate has been used for its low
toxicity, low cost, and spontaneous gelation.44,49 The use of a collagen-HA scaffold is due
to the fact that the native NP is primarily consistent of collagen type II and GAGs.50
Since these are able to gel when desired they have been investigated as a minimally
invasive procedure to treat IDD.
The use of alginate based hydrogels have proven to be effective in cell
encapsulation and having similar aggregate moduli compared to native human NP.44,49
However, through examination of literature and current capabilities these alginate
hydrogels fall short in many aspects of comparing to human NP. GAG content through
studies conducted by Foss and Chou have shown the inability of proteoglycan production
to be established even after a 28 day cell study, with GAG content never increasing past
30µg GAG/mg dry weight tissue. Additionally the % water content tested by Foss after a
28 day study on their cell seeded scaffolds was ~13% whereas in healthy human NP it is
closer to 65%.26,49 Therefore, while alginate scaffolds can gel fast and allow for cell
viability and proliferation they are unable to motivate cells into an NP-like phenotype
with the lack of GAG production.
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1.5.2.3 Decellularization for NP Regeneration
Lastly, scaffold development via decellularization has also been explored and
brings its own advantages and disadvantages. Decellularization is a process in which
cells and antigens are removed via chemical and physical means to leave a scaffold
composed of native ECM. Ideally a decellularized scaffold would have no remnants of
cells and maintain the majority of the ECM however, current literature depicts the how
difficult this is to achieve.51 A balance must be achieved between maintaining the native
ECM and removal of xenogeneic properties. Several animal sources have been used as a
base scaffold for decellularization, porcine and bovine.43,45,52,53
The utilization of a porcine model for decellularization must ensure the removal
of an antigen known as α-gal, which causes a severe immune response within the host.
Previous work by Mercuri, et al., has shown the removal of this epitope while still
maintaining the majority of the natural ECM. However, while the majority of the native
ECM was retained the mechanical properties of the tissue were significantly lower than
that of native human NP. Additionally, during extended cell culture experiments the
tissue lost a majority of the native GAG content due to GAG leaching into the media.
The use of bovine caudal IVDs however does seem promising as a platform for
decellularization. Biochemically before decellularization the NPs start with nearly double
the amount of GAG content, 800µg GAG/mg tissue dry weight, than human NP and also
have very low presence of DNA. Chan et al has shown the use of decellularizing the
entire caudal bovine IVD as a use for a xenogenix scaffold replacement. While they are
able to retain a majority of the native ECM, they were only able to devitalize the cells
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within the scaffold and were unable to fully remove them from the tissue.53 This is
concern due to the simple issue of dead xenogeneic cells still present on a scaffold can
still illicit and immune response.54 Additionally, Iatridis group has developed an
injectable decellularized bovine scaffold for NP treatment. However, these scaffold that
were created failed to even retain greater than 100µg GAG/mg tissue dry weight.
Additionally, the collagen presence within the tissue was greater than 400µg collagen
type II/mg dry weight, indicating an inverse ratio of GAG: HYP within their tissues
whereas in healthy native NP GAG is significantly greater than collagen. Additionally,
these scaffolds were minced and injected via a 25G into an injury site, it would therefore
be fair to assume that this type of scaffold would be unable to support any mechanical
load experienced within the disc, therefore would fail in both aspects of biochemical
composition and mechanical integrity.

1.5.3

Current Animal Models
A multitude of animal models have been utilized to test therapies for IDD.

Current animal models include and are not limited to mice, rats, rabbits, canine, porcine,
ovine, caprine, and non-human primates. Although there are numerous options in animal
selection, it must be done with care and data should be observed cautiously due to
intrinsic differences between animals and humans (IVD size and aspect ratio, variations
in cell population, biomechanics, biochemistry, and variations in anatomical structures).
Currently the most widely used established models are in rats and rabbits.
Investigators looking to obtain valuable clinical information should be wary using these
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animal models however; this is due to the disc space being too small to be of clinical
use.55,56 For clinical relevance a large animal model needs to be used in order to at least
obtain physiological numbers that are more similar to humans. Additionally the disc
space is much larger in larger animal models therefore allowing the implantation of a
material scaled appropriately to the animal. Currently a new model has been
characterized and established using a caprine model. This model allows for the use of
either the cervical or lumbar spine. This model can induce a steady degeneration with the
use of a chondroitinase-ABC solution, or artificially by performing a nucleotomy.57–61

1.6 Summary
NPs are structures specialized for supporting and resisting compressive loads
while also providing stability and flexibility to the entire spinal motion segment.
Unfortunately due to several factors the disc undergo severe degeneration that primarily
begins within the NP. The culmination of this degeneration leads to mechanically
compromised IVDs and detrimental changes in adjacent discs leading towards pain and
significant socio-economic burdens. Current treatment of this condition fails to address
the cause this pathology and merely mitigate the pain. Areas of research aim to further
expound upon the degenerative process and develop novel treatment strategies to
mitigate, halt, or even reverse this degenerative process. The ideal NP replacement would
be of a material that is similar to healthy human NP in regards to biochemistry and
biomechanical properties, which could be used in an early stage intervention to slow or
halt the degeneration.
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The paradigm of tissue engineering is the utilization of cells, scaffolds, and
soluble factors as a means to provide an effective method of creation of a NP
replacement. The utilization of stem cells is the most promising cell source for a NP
tissue-engineering scaffold because and autologous or allogeneic source of NP cells
would cause more harm than healing. With regards to scaffold creation it is necessary
that it is capable of mimicking the biochemical/mechanical properties of the native
human NP. The recreation of the natural human NP properties can be done either by
incorporating ECM components or utilizing xenogeneic sources. While there is no single
correct answer to the issue the utilization of a decellularization method on a NP tissue
does seem the most promising. Decellularization has the key advantages of already
having the natural ECM present needed to guide stem cells down certain pathways and
also retain endogenous factors that have been shown to guide differentiation, cell
migration, and proliferation.51 The caveat with this method of scaffold development is the
balance that must be maintained in the removal of xenogeneic material while also
maintaining the majority of ECM components.
In conclusion, an ideal scaffold should be consistent of the primary ECM
components in the proper concentrations similar to those found in native human NP
ECM.

This

would

most

likely

result

with

a

scaffold

with

comparable

biochemical/mechanical properties compared to native human NP. Accordingly, the
implantation of such a device would allow for the restoration of mechanical function to
the spinal unit without significant issues. Additionally, a scaffold of this nature would
also serve as an ideal carrier of stem cells that could differentiate in to healthy NP-like
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cells prior to implantation. This would allow for the eventual remodeling of tissue and
incorporation into the human NP post implantation. In view of this information, the work
described in the following thesis focus on the development and characterization of a
novel biomaterial to be used as an ideal scaffold for tissue engineering the nucleus
pulposus of the human IVD.
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CHAPTER TWO
MATERIAL AND METHODS
2.1 Tissue Harvest
Caudal IVDs from skeletally mature bovines aged from 2-3 years old were
obtained from a local abattoir and transported on ice to the facilities. Betadine® was
applied to the exterior of the tail to minimize any present bacteria on the tissue. The tails
were then removed of excess flesh and muscle via the use of a scalpel blade in order to
locate the discs within the tails. Once located loppers were used to cut superior of the disc
and inferior to the endplate to expose the whole disc. An 8 mm biopsy punch and a
scalpel blade were used in conjunction to remove the NP from the IVD. Fresh samples
were placed in an empty specimen container and stored at -20˚C to serve as controls for
all experiments. Samples for decellularization, except treatment groups 8-10, were placed
in a specimen container containing one of the formulations of decellularization (decell)
solution, whereas specimens for treatment groups 8-10 were placed in ethanol (EtOH)
(Table 1).
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Table 1: A detailed table of all treatment groups tested describing physical means and solution formation.
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3

3

3

Decell 11

Decell 12

Decell 13*

3

Decell 7*

3

3

Decell 6

Decell 10*

6

Decell 5

3

12

Decell 4

Decell 9

6

Decell 3

3

12

Decell 2

Decell 8

6

Decell 1

3

3

3

3

3

3

3

3

3

6

6

3

3

-

-

-

45 min

60 min

30 min

-

-

-

-

-

-

-

Treatment Number of Time in Decell 70 %EtOH
Group Sonications
Solution
Treatment Time

0.4% (w/v)

2.21 mM

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

0.4% (w/v)

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

0.2% (w/v)

EDTA

1.2% (v/v)

-

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

1.2% (v/v)

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

0.6% (v/v)

-

-

-

1% (w/v)

1% (w/v)

1% (w/v)

2% (w/v)

1% (w/v)

1% (w/v)

1% (w/v)

1% (w/v)

1% (w/v)

1% (w/v)

0.02% (w/v)

-

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

0.04% (w/v)

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

0.02% (w/v)

Triton X-100 Deoxycholic Acid Sodium Azide

Decellularization Solution
RNase

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

1440 mU/mL 1440 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

720 mU/mL 720 mU/mL

DNase

-

720 mU/mL 720 mU/mL

0.4% (w/v) 720 mU/mL 720 mU/mL

-

-

-

-

-

-

-

-

-

-

-

SDS

Nuclease Solutions

Average [DNA]: 7.19 ng/mg
Average [GAG]: 52.63 µg/mg
Histology: Visable Nuclei and Faded Blue ECM
Average [DNA]: 15.26 ng/mg
Average [GAG]: 59.81 µg/mg
Average [DNA]: 10.21 ng/mg
Average [GAG]: 70.67 µg/mg
Average [DNA]: 7.53ng/mg
Average [GAG]: 63.04 µg/mg
Histology:Visable Nuclei and Deep Blue ECM
Average [DNA]: 11.59 ng/mg
Average [GAG]: 83.09 µg/mg
Average [DNA]: 10.45 ng/mg
Average [GAG]: 57.99 µg/mg
Average [DNA]: 33.61 ng/mg
Average [GAG]: 216.98 µg/mg
Histology: Empty Lacunae and Faded Blue ECM
Average [DNA]: 15.59 ng/mg
Average [GAG]: 108.42 µg/mg
Average [DNA]: 9.07 ng/mg
Average [GAG]: 184.53 µg/mg
Average [DNA]: 33.08 ng/mg
Average [GAG]: 208.93 µg/mg
Histology: Nuclei Present and Faded Blue ECM
Average [DNA]: 15.22 ng/mg
Average [GAG]: 133.59 µg/mg
Histology: Nuclei Present and Intense Blue ECM
Average [DNA]: 23.31 ng/mg
Average [GAG]: 71.92 µg/mg
Histology: Nuclei Present and Faded Blue ECM
Average [DNA]: 9.07 ng/mg
Average [GAG]: 205.5 µg/mg
Histology: Empty Lacunae and Deep Blue ECM

Summary of Findings

2.2 Decellularization and Nuclease Solution Creation
All decell solutions were made they day prior to use within the study. All
solutions except for Decell 11 (Table 1) were made in a 50mM Tris, whereas Decell 11
was made in 2.21 mM EDTA and 1x PBS. Decell solutions also were made up of 2%
antibiotic/antimycotic (AB/AM) Nuclease solution for each group was made the day of
and all were created in 1x PBS and 5mM Magnesium Chloride.

2.3 Decellularization Optimization
The decellularization process that is being optimized is of decell method and
solution (Treatment Group 6) adapted from Mercuri et al.45 Briefly this decell
procedure calls for samples to be placed in containers containing decell solution and
sonicated for 10 minutes once every 24 hours over a 72 hour period and placed on an
orbital at 150 RPM for 72 hours with solution changes occurring every 24 hours. After 72
hours samples are placed in dH2O, sonicated for 10 minutes and then placed on an orbital
shaker at 150 RPM for the duration of one hour. Following the hour in dH2O samples are
then placed in 70% ethanol for 30 minutes then washed again in dH2O for 30 minutes all
while on the orbital shaker. Samples are then placed in a nuclease solution at 37˚C for 48
hours. After 48 hours samples are then washed for 1 hour in dH2O with solution changes
every 30 minutes. The changes made to this procedure and solutions (as seen in Table 1)
were to the total time in decell solution, total number of sonication, concentrations and
make up of both decull and nuclease solutions, treatment with SDS, and the use of
pretreatment in EtOH.
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Thirteen different treatment groups were established (Table1) and were screened
by measuring the DNA content and glycosaminoglycan (GAG) of the treated tissues. The
assays used to identify DNA and GAG content was a PicoGreen® assay and agarose gel
electrophoresis for DNA and a dimethymethylene blue assay (DMMB) for GAG. The
determination of successful removal of DNA for decelularization of the samples was
established to contain less than 50 ng/mg DNA per tissue dry weight and less than 200 bp
DNA fragment length.51 However, there must be a balance of removal of DNA and
maintaining the natural ECM, therefore at least 200µg/mg GAG per dry weight tissue
was established as the guideline for maintaining enough natural ECM. Lastly, histology
was employed to observe any remaining cell remnants within samples and to qualitatively
evaluate the GAG content. When the above criterion was met acceptable treatment
groups continued for further evaluation and characterization.

2.4 Biochemical Analysis
Cross sections from all samples from decell treatment groups and fresh tissue
were stored at -80˚C overnight and lyophilized for two days. Samples were then digested
in a PBE buffer containing Papain (5mM L-Cysteine, 100mM Dibasic Phosphate Buffer,
5mM EDTA, 125µg/mL Papain, pH 6.5) for 24 hours at 65˚C and were vortexed
periodically until the tissue was fully digested. All values obtained were normalized to
tissue dry weight.
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2.4.1 PicoGreen® Analysis for dsDNA
Total DNA content of fresh bovine NPs (n=6) and treatment groups 1-13 (n=6)
were quantified using a PicoGreen® assay. Papain samples were first diluted by 2x in a
1X TE buffer, and then 100µL of this mixture was taken and added to a black-well well
plate in order to prevent fluorescent bleaching and interference from other samples in
adjacent wells. Next 100µL of the PicoGreen® reagent was added to each well containing
solution and incubated in the dark for 5 minutes. The plates were then read at an
excitation of 480nm and emission of 520nm. DNA (expressed as DNA ng/mg sample dry
weight) was determined using serial dilutions of a known DNA content provided within
the PicoGreen® kit.

2.4.2 Agarose Gel Electrophoresis
In order to observe if there were any residual base pairs of DNA remaining the
papain digested samples of both fresh (n=3) and treated (n=3) NPs first purified using a
Qiagen DNeasy® Blood & Tissue extraction kit in accordance with the protocol provided
by the manufacture. The DNA was visualized using an ethidium bromide agarose gel. All
samples were compared to a DNA standard to determine the size of the remaining base
pairs of DNA present within the tissue. In order to cover a wide range of base pairs two
separate gels were created. A wide range ladder (300-24,000bp, exACTGene 24kb) was
used in a 1% agarose gel and was run at 100V for 60 minutes. A low range ladder (10300bp, O’GeneRuler Low Range DNA) was used in a 5% agarose gel and was run at
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75V for 60 minutes. Gels were then imaged in a bio-imager using an ethidium bromide
filter to detect the DNA bands.

2.4.3 DMMB Analysis for GAG
Papain digested samples of fresh (n=6) and treated (n=6) NPs were diluted by
1000x and 100x respectively in PBE buffer (5mM L-Cysteine, 100mM Dibasic
Phosphate Buffer, 5mM EDTA, pH 7.5). From this mixture 50 µL’s were taken and
added to a 96-well plate, then 200µL of DMMB reagent (40mM NaCl, 40mM Glycine,
46µM DMMB, pH 3.0) was added to each well containing either sample or standard. The
plates were then read at an absorbance of 525 nm. GAG (expressed as GAG µg/mg
sample dry weight) was determined via a standard curve developed from different
dilutions of known concentrations of chondroitin sulfate.

2.4.4 Hydroxyproline Analysis
Fresh bovine NPs (n=3) and treated NPs (n=6) had their collagen content
quantified by using a hydroxyproline (HYP) assay following the manufacturers protocol
(Sigma – MAK008) with the addition of a dilution step after charcoal purification. The
supernantent of both fresh and treated NPs were diluted in 12M HCl to create a 100x total
dilution. HYP content (expressed as [HYP] µg/mg sample dry weight) was calculated
using a standard of serial dilutions of a known concentration of HYP provided in the kit
with the optical absorbance being read at 550nm.
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2.5 Histology and Immunohistochemistry (IHC)
Cross sections of both fresh bovine NPs and treated NPs were fixed in 10%
neutral buffered formalin for 24 hours. Fixed samples were then washed in 1X PBS with
0.01% sodium azide for 30 minutes. Tissues were then soaked in a 15% sucrose solution
at 4˚C overnight. After soaking samples were placed in a 30% sucrose solution for 2
hours at 4˚C, then were placed in a 50/50 30% sucrose and OCT solution for 2 hours at
room temperature. Lastly, samples were placed in OCT for 2 hours then transferred to
OCT molds for cryosectioning at -20˚C until solid. Cryosections were then sectioned at
8µm and were attached to positively charged slides and stored at -20˚C until needed for
staining. All slides were imaged using a Zeiss Axio Vert.A1.

2.5.1 IHC for Collagen-II
Frozen sections of both fresh (n=3) and treated (n=3) NPs were fixed for 20
minutes in cold acetone. Slides were then processed according to the provided protocol
for the Vectastain® ABC Elite Kit Rabbit IgG and DAB substrate kit (SK4100). The
antibody used for detection was a rabbit polyclonal to collagen-II specific for bovine
(Abcam – ab78482). Sections were developed in DAB for 5 minutes, washed and then
counterstained in a 50/50 hematoxylin/water solution for 30 seconds. Sections were then
rinsed, dehydrated, cleared, and mounted.
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2.5.2 Alcian Blue Counterstained with Nuclear Fast Red
Frozen sections of both fresh (n=6) and treated (n=6) NPs were rinsed in tap
water until sheeting occurred. Samples were then placed in 3% acetic acid for 1 minute
then placed in 1% alcian blue in 3% acetic acid (pH 2.5) for 3 minutes. Slides were then
rinsed in tap water for 1 minute and then rinsed in distilled water until clear. Sections
were then counterstained in 0.1% nuclear fast red for 2 minutes, rinsed in tap water for 1
minute, then dehydrated mounted and coverslipped.

2.5.3 DAPI
Frozen slides of both fresh (n=3) and treated (n=3) NPs were rinsed in 1X PBS
for 1 minute then placed in a 300nM DAPI solution for 5 minutes in the dark. Slides were
then washed in PBS and were transported for imaging under a fluorescent microscope
immediately.

2.5.4 Ethidium Bromide Staining
Tissues for both fresh (n=3) and treated (n=3) NPs were placed in a mixture of
4mM Calcein AM and 2mM Ethidium Bromide-III in PBS for 30 minutes. Tissues were
then thinly sectioned using a scalpel blade and imaged under a fluorescent microscope.
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2.6 Mechanical Testing
Both tissues were frozen at -20˚C and then placed in an OCT mold and sectioned
to a thinckness of ~2µm for all testing. Samples were then allowed to thaw and free swell
in the testing tank solution consisting of 1X PBS and 1% protease inhibitor. All testing
was performed on a Bose Electrofoce® 3200 series with a 1000g load cell.

2.6.1 Unconfined Compression
Unconfined compression was used to conduct a stress relaxation experiment to
determine the equilibrium modulus and percent relaxation was adapted from multiple
sources.9,26 Specimens were allowed to free swell for 30 minutes and then were placed in
between two non-porous platens. Samples were then loaded to 2.5N and were allowed to
reach equilibrium. Once the sample was equilibrated the height was recorded and used as
the initial height for testing, this was done for each individual sample. The strains that
were tested were 8%, 12%, and 16%. Strains were applied instantaneously and samples
were allowed to relax for 20 minutes (the determined equilibrium from previous trials)
until the next strain was applied. Data was collected using level crossing with each
∆0.025N being recorded.

2.6.2 Unconfined Dynamic Mechanical Analysis (DMA)
DMA testing was used to determine the complex, storage, and loss modulus and
phase angle of both the fresh bovine NP and treated scaffolds. Similarly to unconfined
compression samples were loaded to 2.5N and height was obtained at equilibrium.
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Samples were preconditioned at 5% strain for 10 cycles. The height and width of each
sample was placed into the DMA program and was set to run at 0.01, 0.1, 1, and 10 Hz
with a 20-minute relaxation between frequencies. Once testing was concluded the
program calculated the desired values.

2.7 Cell Studies
2.7.1 Scaffold Cytotoxicity
Scaffolds were first sterilized in 0.01% paracetic acid then washed three times at
15 minutes each in 1X sterile PBS. Scaffolds were then placed in a solution of 50% FBS,
48% DMEM, and 2% AB/AM for 24 hours. Human amniotic mesencymal stem cells
(hAMSCs) were seeded at a density of 2,000 hAMSCs/mm2 for each scaffold. Once
seeded scaffolds were incubated for 3 hours to allow time for cells to settle and integrate,
once 3 hours were over standard media was added to each well. On days 3,7 and 14 a
live/dead assay was performed (n=3, time point). A Viability/Cytotoxicity assay for
live/dead cells kit was used and performed following the manufactures instructions.
Seeded scaffolds were then thinly section using a scalpel blade and imaged under a
fluorescent microscope. Three images of both live and dead were then taken for each
scaffold. Counts of cells were performed by manually counting live and dead cells.
Percent viability was determined by dividing the difference of live and dead cells over the
amount of live cells.
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2.7.2 Scaffold Crosslinking
ABNP scaffolds crosslinked in 30:6 EDC: NHS for 30 minutes. Scaffolds were
then washed three times for 15 minutes each. After washing scaffolds were sterilized
utilizing the method previously mentioned in 0.1% paracetic acid and placed in a solution
of 50% FBS, 48% DMEM, and 2% AB/AM for 24 hours.

2.7.3 Syringe Gauge Viability Study
In order to determine the best syringe to use for cell injection different sized
gauges were evaluated to determine the viability of cells after passing through the
syringe. Cells were aliquoted into 1mL amounts to create a 1 x 106 cells/mL solution into
1.5mL microfuge tubes. First a 21G was utilized, if cells had high viability than a higher
gauge syringe would be tested and vice versa, to suck up the solution and then was
injected into a separate tube. The injected solution was tested using a trypan blue
detection method and viability was determined. If the viability was high than a 28G
needle would be tested and if the viability was low a 16G needle would be tested. The
purpose of this is to best determine the smallest syringe size to inject cells into ABNP
scaffold.

2.7.4 Cell Injection Study
Similarly to the cytotoxicity study scaffolds were sterilized and were stored in a
50/40/2 solution of FBS/ DMEM/ AB/AM. A seeding density of of 2,000 hAMSCs/mm2
for each scaffold was also used. Scaffolds were injected in 3 separate areas using a 28G
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syringe. Each scaffold could be filled with 100-150µL of the cell solution and the
remainder was seeded directly onto the scaffold. After seeding scaffolds were placed in a
24-well plate for 3 hours to allow cells to settle and integrate into the scaffolds before
media was added to the wells. On days 3 and 14 scaffolds underwent live/dead staining to
determine % viability and also were processed for frozen sectioning to stain for cell
penetration.

29

CHAPTER THREE
RESULTS
3.1 Decellularization Optimization Screening Analysis
The effectiveness of all decellularization groups were screened by measuring the
GAG and DNA content of the tissues to evaluate the maintenance of this critical
extracellular matrix component while efficiently removing cellular remnants. The
decellularization procedures utilized and screening results are summarized in Table 3.1.
Optimized treatment groups were defined as those that maintained at least 200µg/mg of
GAG and less than 50ng/mg DNA.
From the initial testing of treatment groups 1-9 there were significant differences
with all groups when compared to fresh bovine NP for both GAG retention and DNA
removal (Figure 3.1A, 3.2A), additionally there were significant differences found
among treatment groups (Figure 3.1B, 3.2B). Treatment group 9 significantly retained
more GAG (235.03 ± 56.44 µg GAG/mg tissue dry weight) than treatment groups 1-6.
Treatment groups 7 and 8 however, were not significantly different, 131.55 ± 19.26 and
123.15 ± 30.86µg GAG/mg tissue dry weight respectively, from treatment group 9 with
respect to GAG content. Although all treatment groups had less than 16ng DNA/mg
tissue dry weight there were significant differences between groups (Figure 3.2B).
Treatment groups 2 and 8 had the largest values of DNA still present, 15.26 ± 5.85 and
15.6 ± 2.9DNA/mg tissue dry weight respectively, and therefore had significant
differences with groups that were able to remove higher amounts of DNA. Treatment
groups 7 and 9 as well as treatment group 8 were able to retain the most GAGs and were
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therefore groups of interest for DNA removal. The DNA content for both treatment group
7 and 9 was 8.44 ± 2.14 and 9.08 ± 0.39ng DNA/mg tissue dry weight respectively.
Although treatment group 9 seemed like the ideal candidate as an optimal
decellularization procedure macroscopically the tissue seemed to harden and lost its gellike properties, whereas treatment group 8 was still a gel-like material. With this
information on both GAG and DNA content, as well as a histological assessment (Figure
3.3) treatment group 7 and a combination of treatment groups 8 and 9 were chosen to
quantify, due to the ability of these groups retention of the most GAG content while still
removing a significant amount of DNA.
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A

*

B

Figure 3.1: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP
(p>0.05) (B) Quantification of GAG content of treatment groups compared to each other (p>0.05)
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B

Figure 3.2: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP
(p>0.05) (B) Quantification of DNA content of treatment groups compared to each other (p>0.05)
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Figure 3.3: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 1 (C) 200x (D) 400x image of treatment
group 4 (E) 200x (F) 400x image of treatment group 7 (G) 200x (H) 400x image of fresh bovine NP
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A second optimization study was performed to expand numbers for treatment
group 7, with the additions of 45-minute ethanol prewash, hypothesized from previous
observations that ethanol dehydrates the scaffolds allowing for more decellularization
solution to be absorbed by the scaffold during treatment. Additionally, another treatment
group was created to observe the result of removing deoxycholic acid from the base
formula of decellularization previously described. The choice to remove deoxycholic acid
from the base decellularization solution was hypothesized that the ionic nature of the
component was disrupting too much of the native ECM during the decellularization
procedure. From this the only significant differences observed were from the tissue
compared to the treatment groups for GAG retention and DNA removal (Figure 3.4, 3.5).
All treatment groups had less than 25ng DNA/mg tissue dry weight additionally both
treatment groups 7 and 10 had higher than 200µg GAG/mg tissue dry weight with
treatment group only maintaining ~187µg of GAG (Figure 3.4). However, from
histology treatment group 11 had stained more intensely blue, indicating higher GAG
concentration, than treatment groups 7 and 10 (Figure 3.6). Therefore an additional
round of optimization was decided upon to test a high concentration of decellularization
solution without the deoxycholic acid component, this is due to the histology of treatment
group 11 and that treatment group 11 was not significantly different from treatment
groups 7 and 10. In addition, a SDS decellularization group, treatment group 12, was
added to compare how our decellularization solution compares against a widely used
method of decellularization.
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Figure 3.4: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP (p>0.05)
(B) Quantification of GAG content of treatment groups compared to each other (p>0.05)
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B

Figure 3.5: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP (p>0.05)
(B) Quantification of DNA content of treatment groups compared to each other (p>0.05)
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Figure 3.6: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 7 (C) 200x (D) 400x image of treatment
group 10 (E) 200x (F) 400x image of treatment group 11 (G) 200x (H) 400x image of fresh bovine NP
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A final study was performed to ensure there was at least an n=6 for all treatment
groups. All treatment groups, except for treatment group 12 (SDS), were able to retain
greater than 200µg GAG/mg tissue dry weight with only treatment group 12 being
significantly different from the other groups (Figure 3.7). Interestingly, all groups except
for treatment group 12 had lower than 35ng DNA/mg tissue dry weight with treatment
group 13 only having less than 10ng DNA/mg tissue dry weight remaining. Treatment
group 12 however had greater than 70ng DNA/mg tissue dry weight remaining within the
tissue (Figure 3.8). Additionally the histology for treatment group 13 depicted intact
empty lacunae (Figure 3.9). Accordingly, three decellularization treatment groups (7, 10
& 13) were selected based on the criterion set prior (Table 1). Additional characterization
to confirm the removal of residual DNA fragments was evaluated via agarose gel
electrophoresis.
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Figure 3.7: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP (p>0.05)
(B) Quantification of GAG content of treatment groups compared to each other (p>0.05)
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Figure 3.8: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP (p>0.05)
(B) Quantification of DNA content of treatment groups compared to each other (p>0.05)
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Figure 3.9: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 7 (C) 200x (D) 400x image of treatment
group 10 (E) 200x (F) 400x image of treatment group 12 (G) 200x (H) 400x image of treatment group 13
(I) 200x (J) 400x image of fresh bovine NP
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3.2 Biochemical Analysis of Optimal Decellularization Treatments
3.2.1 DNA Quantification
Evaluation of double stranded bovine DNA demonstrated significant reductions
(p<0.01) in treatment groups 7, 10, & 13 as compared to fresh tissue. These groups, with
no significant differences between them, contained 33.61 ± 9.49ng, 33.08 ± 11.57ng, and
9.07 ± 1.95ng DNA/mg sample dry weight, respectively (Figure 3.8B). Interestingly,
samples treated with SDS did not show significant reductions in DNA content, which
contained 71.31 ± 30.59ng DNA/mg dry weight. Compared to the DNA within fresh
bovine NPs (125.45 ± 11.81ng DNA/mg sample dry weight) there was a 73.2 ± 7.56%,
73.63 ± 9.22%, & 92.77 ± 1.54% reduction in DNA content in treatment groups 7, 10,
and 13 respectively.

3.2.2 Qualitative Measurement of DNA
Detection of DNA fragments ranging from 10-24,000bp was evaluated for
treatment groups 7, 10, and 13 and compared to fresh bovine NP samples. No visible
bands were observed in either agarose gel for treatment groups 10 and 13 indicating no
residual DNA fragments, whereas DNA bands were visible for fresh and treatment 7
(Figure 3.10).

43

10

7

13

1% Agarose Gel
300-24,000 bp

5% Agarose Gel
10-300 bp

Figure 3.10: Agarose gel electrophoresis depicting the presence of DNA in fresh bovine NP and in
treatment group 7 (white box), and the lack of DNA fragments in treatment groups 10 and 13 tested from
10-24,000bp.

3.2.3 GAG Quantification
GAG quantification of decellularized bovine NP, with no significant differences
between groups, demonstrated the retention of 216.98 ± 31.06µg, 2018.93 ± 24.96µg,
71.92 ± 5.18µg, and 205.5 ± 16.00µg GAG/mg sample dry weight within treatments 7,
10, and 13 respectively (Figure 3.7B). These values were statistically different when
compared to fresh bovine NP tissue (677.66 ± 93.22 µg GAG/mg sample dry weight)
(Figure 3.7A). SDS treatment resulted in dramatic reduction in GAG content (71.92 ±
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5.18µg) compared to treatments 7, 10, and 13. Decellularization resulted in an average
reduction GAG content of 67.98 ± 4.58%, 69.17 ± 3.68%, & 69.68 ± 2.36% in treatment
groups 7, 10, and 13 respectively. Taken together with the aforementioned data treatment
group 13 was selected as the optimal decellularization method investigated herein, thus
further biochemical, histological and mechanical analysis was performed on samples
subjected to this treatment group (highlighted in Table 1).

3.2.4 Hydroxyproline Quantification
Hydroxyproline (HYP) quantification on samples treated with procedure 13 had
significantly higher HYP content per dry mass as compared to fresh bovine NP tissue
(p<0.05) (Figure 3.11). Treatment group 13 contained nearly double the average amount
of hydroxyproline as compared to fresh bovine NPs (13.87 ± 1.14µg & 8.63 ± 0.24µg
HYP/mg sample dry weight). Additionally, the GAG to HYP ratio was calculated to be
approximately 15:1 for decellularized samples whereas, fresh bovine NP tissue had an
apparent ratio of 79:1.
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Figure 3.11: Hydroxyproline assay quantification of [HYP] content found in treatment group 13 and fresh
bovine NP demonstrating a significant increase (*p<0.05) in [HYP].

3.2.5 IHC for Collagen-II
IHC for collagen type 2 (Col-II) confirmed the presence of Col-2 within both
treatment group 13 and fresh bovine NP. Histological images illustrated intense brown
(positive) staining in both groups as compared to negative controls (Figure 3.12).
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A

B

C

D

Figure 3.12: Immunohistochemistry for Col-II tissue from treatment group 13 (A) 200x (B) 400x
compared to fresh tissue (C) 200x (D) 400x. Inserts are negative controls.

3.2.5 Macroscopic & Histological Evaluation
Macroscopically both fresh bovine NPs and the NPs from treatment 13
maintained their shape and exhibited a hydrated status (76.58 ± 1.4% and 94.56 ± 0.37%
percent water content respectively) (Figure 3.13). Qualitative histology of the fresh
bovine NPs depicted the presence of cells in clusters / islands. The fresh bovine NPs also
stained more intensely with alcian blue as indicated by a deeper blue staining as
compared with the treatment 13 NPs (Figure 3.9). Within the matrix of the treatment 13
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NPs it is clearly visible that there exist empty lacunae with no visible cell remnants.
DAPI staining was performed to re-confirm the lack of cell nuclei present in the
treatment 13 NPs (Figure 3.14). The presence of nuclear material is clearly evident in the
fresh bovine NP. The treatment 13 NPs not only depicts no fluorescence of nuclear
material but also depicts empty lacunae further re-confirming the removal of nuclear
material. Lastly, an ethidium bromide (EtBr) stain was used to once again confirm the
lack of residual DNA within the treatment 13 NPs (data not shown). Therefore with this
confirmation of complete cell removal the treatment 13 NPs were hereafter referred to as
acellular bovine nucleus pulposus (ABNP) scaffold.

Figure 3.13: Macroscopic image of (left) fresh bovine NP and (right) an NP from treatment group 13.
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D

E

F

G

H

Figure 3.14: DAPI staining to induce fluorescence of cell nuclei. (A) 200x (B) 400x image of treatment
group 7 (C) 200x (D) 400x image of treatment group 10 (E) 200x (F) 400x image of treatment group 13
(G) 200x (H) 400x image of fresh bovine NP
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3.3 Mechanical Analysis
3.3.1 Unconfined Compression
Equilibrium modulus, and percent relaxation of both ABNP scaffolds and fresh
bovine NP were determined by unconfined compression stress relaxation testing (Figure
3.15). These values for the ABNP scaffold were determined to be 5.6 ± 1.12kPa and
82.26 ± 3.7%. The values for fresh bovine NP were determined to be 50.75 ± 6.97kPa
and 78.01 ± 3.81%, respectively (Table 2).

Property
% Water Content (%)
Equilibrium Modulus (kPa)
% Relaxation (%)

ABNP
94.56 ± 0.37
5.6 ± 1.12
82.26 ± 3.7

Table 2: Values obtained from unconfined compression testing
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Fresh Bovine
76.58 ± 1.47
7.08 ± 0.64
78.01 ± 3.81

A

B

Figure 3.15: (A) ABNP (B) Fresh Bovine NP. Representative curve of stress relaxation during unconfined
compression testing. Peaks are at 8, 12, & 16% strain respectively.
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3.3.2 Dynamic Mechanical Analysis (DMA)
The complex, storage, and loss moduli as well as the phase angle of the ABNP
scaffolds and fresh bovine NPs were evaluated and compared using DMA (Table 3). No
statistical difference was observed when comparing both groups. There did appear to be a
frequency dependent relationship for both sample types. The range of values observed for
ABNP scaffold for the complex, storage, and loss moduli and phase angle were 6.313.5kPa, 6.3-13.5kPa, 1.6-4.7kPa, and 14.9-26˚, respectively over the frequencies tested
(Figure 3.16A-B). Fresh bovine NP values tended to be similar compared to ABNP and
were found within the ranges of 6.36-13.99kPa, 5.99-13.13 kPa, 2.12-4.55kPa, and
15.36-20.16˚, respectively (Figure3.16C-D).
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Frequency

0.01

Complex Modulus (kPa)
0.1
1

10

ABNP

6.59 ± 1.64 8.02 ± 1.96 9.96 ± 2.22 13.52 ± 2.82

Fresh

6.36 ± 1.13

Frequency

0.01

8.56 ± 1.4 10.92 ± 1.59
Storage Modulus (kPa)
0.1
1

13.99 ± 2

10

ABNP

6.35 ± 1.62 7.85 ± 1.92 10.25 ± 2.65 12.11 ± 2.85

Fresh

5.99 ± 1.11

Frequency

0.01

8.23 ± 1.38 10.51 ± 1.56 13.13 ± 1.9
Loss Modulus (kPa)
0.1
1

ABNP

1.68 ± 0.29 1.83 ± 0.32 2.45 ± 0.41

Fresh

2.12 ± 0.3

Frequency

0.01

10
4.8 ± 0.89

2.29 ± 0.36 2.86 ± 0.48 4.55 ± 0.83
Phase Angle (Degree)
0.1
1

10

ABNP

17.3 ± 1.34 14.99 ± 1.17 16.66 ± 1.59 26.44 ± 3.53

Fresh

20.16 ± 1.61 15.93 ± 1.77 15.36 ± 1.96 18.90 ± 2.37

Table 3: Range of values for the viscoelastic properties obtained for both the ABNP and Fresh Bovine NP
during DMA.
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(A)

Loss Modulus
Complex Modulus
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Modulus (kPa)

40

Storage Modulus

Phase Angle (Deg)

20

10

5

0.01

20

1

10

10

5

0.1
1
Frequency (Hz)

0.1
1
Frequency (Hz)

10

0.01

0.1
1
Frequency (Hz)

10

(D)

Complex Modulus

0.01

0.01

40

Loss Modulus

15

0
0.001

20

0
0.001

10

Storage Modulus

(C)
Modulus (kPa)

0.1
Frequency (Hz)

Phase Angle (Deg)

0
0.001

(B)

30

30

20

10

0
0.001

10

Figure3.16: Dynamic mechanical analysis of the ABNP scaffold compared to fresh bovine NP tissue. (A &
C) Representative curve of the complex (E*), Storage (E’) and Loss (E’’) moduli as well as (B & D) Phase
angle (δ) of ABNP samples compared to fresh bovine NP tested at 8% strain at different frequencies. No
significant differences found at any point.

3.4 Cell Studies
3.4.1 ABNP Cytotoxicity Study
ABNP scaffold cytotoxicity was evaluated by seeding human amniotic
mesenchymal stem cells (hAMSCs) onto the surface of the ABNP scaffold and cultured
to 14 days. Live/dead fluorescence indicated cell viability to be 94%, 87%, and 95% at
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days 3, 7, and 14, respectively (Figure 3.17). However, there was no noticeable cell
penetration into the scaffolds throughout the duration of the study.

A

B

C

Figure 3.17: Live/Dead staining was performed on days 3, 7, & 14 with percent viability at 94, 87, & 95%
cell viability, respectively. (Top) Graph of the cell viability throughout the study. (Bottom) Representative
images live/dead stained cell seeded scaffolds.
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3.4.2 Cell Injection Studies
Cell injection, via a 28G syringe previously determined as optimal, was
performed on both ABNP and EDC/NHS (30:6) cross-linked ABNP scaffolds and
cultured to 14 days. Live/dead fluorescence indicated cell viability at day 3 was 91% and
73% for the ABNP and cross-linked ABNP scaffold respectively (Figure 3.18). Percent
viability for day 14 of the ABNP and cross-linked ABNP scaffolds was 97% and 65%
respectively.
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A

B

C

D

Day 3

Day 14

100

E

Percent Viability (%)

80

60

40

20

0
ABNP

Crosslinked
Day 3

ABNP

Crosslinked
Day 14

Figure 3.18: Representative images of live/dead staining of day 3 of (A) ABNP scaffolds (200x) and (B)
cross-linked ABNP scaffolds (200x) and day 14 (C) ABNP scaffolds (100x) and (D) cross-linked ABNP
scaffolds (100x) Red lines are indicative of the syringe pathway. (E) Graph of percent viability of both day
3 and day 14 ABNP and cross-linked ABNP scaffolds.
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CHAPTER FOUR
DISCUSSION
Ideal methods of decellularization would be capable of removing the majority of
host cells and their remnants while also preserving the native ECM. Preservation of the
native ECM is essential since it represents the secreted products of resident cells and has
been shown to provide cues that affect cell migration, proliferation, and differentiation.51
However, current methods of decellularization are unable to fully maintain the natural
ECM while also removing a significant portion of cells. Considering this, bovine caudal
IVD NP tissue was chosen for decellularization since the natural ECM has higher
quantities of GAG when compared to healthy human NP, which varies from 200-600µg
GAG/mg Dry weight tissue,62 and also have a similar composition, resting stress, and
height to diameter ratio when compared to human lumbar discs.63 Herein this research
compares and screens 13 different decellularization conditions and assesses their efficacy
to decellularize bovine NP tissue while also maintaining the critical NP matrix
composition. Initial acceptance criteria demonstrating an effective decellularization
process included the maintenance of NP GAG content of 200µg GAG/mg tissue dry
weight concomitant with residual DNA content of less than 50ng DNA/mg dry tissue
weight. It has been suggested that such a low concentration of residual nucleic acid
should not illicit an immune response.51,62 After passing the initial screening process
additional methods were used to fully quantify any remaining DNA fragments and cells
as well as collagen type II content, another critical component of the native NP.
Additionally, once a single ideal procedure was identified scaffolds from that group
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underwent a series of mechanical testing, adapting many protocols in literature,9,26,64 to
thoroughly investigate the viscoelastic properties of the developed material Lastly, it was
critical for the scaffold developed to allow for the survival and penetration of cells, which
would play a pivotal role in the regeneration of the NP tissue.

4.1 Decellularization Optimization
The utilization of decellularization as a procedure to create a biomimetic scaffold
does come with it’s own advantages and disadvantages. The challenge associated with
this type of procedure is the balance of maintaining the ECM while removing all DNA to
minimize any chance for an immunogenic host response. The preservation of GAG was
deemed critical for this type of procedure since it is key to the function of the NP, which
relies upon the osmotic potential that is generated by the GAGs, associated with the
proteoglycan aggrecan, to create a structure ideal for load distribution.65 Currently,
groups have shown the retention of the native ECM but only devitalized cells and failed
to remove cells entirely.53 Additionally, others have also shown the acceptable removal of
DNA but failed to maintain the majority of the native ECM.43 Groups have used a
multitude of methods for decellularization including chemical and physical means for
removal of cells.43,45,51,53 In order to optimize the decellularization procedure different
solutions, time, and physical means were evaluated in order to determine an ideal
procedure.
From the initial screening study of treatment groups 1-9 several factors were
evaluated to determine any significant differences amongst groups. All treatment groups
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were significantly different from the fresh bovine NP controls with respect to DNA
removal and GAG loss (Figure 3.1, 3.2). Significant differences in regards to DNA
removal within groups however were interesting. Treatment groups 1 and 2, the only
difference being amount of sonications, 6 & 12 sonications respectively, were
significantly different from each other in regards to DNA removal. Treatment group 1,
even though it experienced less sonications than treatment group 2 had significantly less
DNA. Additionally treatment group 8, 30-minute ethanol pre-wash, had significantly
higher DNA, this could be due to the DNA not having enough time to fully precipitate
out of the scaffold, when compared to treatment groups 1 and 4. Ethanol was initially
used to provide a method to dehydrate the bovine NPs in order to allow more
decellularization solution to be absorbed by the tissue but also attributed to GAG
retention and removal of DNA due to ethanol’s nature to crosslink allowing GAGs to be
retained without sacrificing the removal of DNA due to ethanol’s ability to precipitate
DNA out of cells by dehydrating the area around the DNA,66 which worked in the case
of treatment group 9, however in treatment group 8 the decellularization time and number
of sonications were lower compared to that of treatment groups 1 and 4, therefore only 30
minutes in a pre-wash of ethanol was not enough to cut down in decellularization time
whereas one hour in ethanol was comparable. With regards to GAG retention treatment
group 9, one hour ethanol wash, was significantly able to retain more GAG than
treatment groups 1-6 and was comparable to treatment groups 7 and 8. Additionally,
other trends were noted such as increasing the concentration of the decellularization
solution was also able to maintain high amounts of GAG while also reducing DNA.
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There were also no noticeable effects of total time in decellularization and increasing the
concentration of nuclease solution
From these initial studies treatment group 7 and a combination of treatment group
10 utilizing a 45-minute ethanol prewash, which hypothesized from previous
observations that this median time of ethanol treatment will be enough to allow bovine
NPs to dehydrate and crosslink long enough to preserve GAG and remove DNA.
Additionally, treatment group 11 was created to observe the result of removing
deoxycholic acid; an ionic detergent, from the base formula of decellularization
previously described. This was decided upon in order to minimize any destruction a
charged detergent can do to the charged components of the native ECM. From this all
three groups had no significant differences amongst each other however treatment group
11, base decellularization solution without deoxycholic acid, trended to have lower
values of GAG retention and higher DNA removal and also stained more intensely blue
compared to treatment groups 7 an 10 via histology indicating a more preserved ECM
matrix (Figure 3.6). Therefore in order to increase GAG concentration a higher
concentration decellularization solution was utilized with no deoxycholic acid added into
the solution. Additionally, to compare our formation of deceullularization solution the
addition of an SDS group was added, since it is a commonly used method of
decullariaztion.43,53
From the final optimization of decellularization studies treatment groups 7, 10,
and 13 all had GAG content greater than 200µg GAG/mg dry weight and DNA content
lower than 50 ng DNA/mg dry weight (Figure 3.7, 3.8). More impressively treatment
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group 13 had DNA content lower than 10ng DNA/mg dry weight. Surprisingly treatment
group 12, the SDS group, had more DNA than some previously treated groups and
unsurprisingly removed the majority of GAG from the tissue, this however could be from
a difference of procedure utilized. Observations via histology found that treatment group
13 was able remove nuclei from the tissue while also maintaining the lacunae (Figure
3.9G-H). From these studies treatment groups 7, 10, and 13 were selected to continue
with further confirmation of decellularization using an agarose gel electrophoresis assay
and DAPI staining.

4.2 Confirmation of Decellularization
The removal of cellular components and the confirmation of removal are
imperative for xenogeneic materials. Even though the healthy IVD is considered an
immune privilege region, the results of degeneration and surgery can create a site of
inflammation that should be minimized as much as possible.54 We evaluated this several
ways and determined that treatment group 13 was the most ideal candidate to continue
characterizing. Confirmation of the full removal of DNA, DNA fragments, and cells was
confirmed using a low and high molecular weight agarose gel electrophoresis, and alcian
blue counterstained with nuclear fast red, DAPI, and ethidium bromide staining. The
purpose performing an agarose gel was to ensure there were no DNA fragaments greater
than 200bp left within the tissue since it is generally viewed that DNA containing
fragments greater than 200bp might still cause an immunogenic response if
implanted.51,54
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The utilization of alcian blue counterstained with nuclear fast red, DAPI, and
ethidium bromide staining for cell nuclei was performed to observe more clearly any
remnants of nuclei and confirm no visible presence of cell nuclei which is necessary in
order to claim a scaffold fully decellulairized.51 All but treatment group 13 had
observable nuclei within the ECM. Images from treatment group 13 clearly show empty
lacunae where nuclei would have been prior to decellularization. Therefore with all the
data considered prior, treatment group 13 will now be referred to as an acellular bovine
NP (ABNP) scaffold.

4.3 Biochemistry of the ABNP Scaffold
As previously discussed the ABNP scaffold was able to retain greater than 200 µg
GAG/mg tissue dry weight with less than 10ng DNA/mg tissue dry weight. Compared to
a healthy human NP the GAG content found within ranges from 200-600µg GAG/mg dry
weight tissue, whereas in severely degenerated human NP the GAG content has been
reported to be as low as 18µg/mg dry weight and on average 87µg/mg dry weight.62 The
significant retention of GAG is critical for the maintenance and function of the NP
tissue.6,18,67 Without high levels of GAG in the NP it will lose its essential function. GAG
is primarily responsible for creating the osmotic properties and swelling needed to
transfer compressive loads, but also prevents nerve and blood vessel ingrowth.11,13,15,65
Also critical to the structure of the NP is the presence of collagen type II and the resulting
ratio of GAG: HYP.6 Both IHC for collagen type II and a HYP assay were performed to
evaluate these properties. IHC was able to detect a strong presence for collagen type II
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and the HYP quantified the concentration to be 13.87 µg HYP/mg tissue dry weight. This
yields a ratio of approximately 15:1 GAG: HYP, which is lower than what is found
within a healthy human NP that has a ratio of 27:1 GAG: HYP but higher than an aged
disc that has a ratio of 5:1 GAG: HYP.6 This ratio however, is much higher than what
others in literature have been trying to recapitulate.43,68–70

4.4 Viscoelastic Properties of the ABNP Scaffold
The viscoelastic properties of the native human NP have been shown to influence
both the mechanical behavior of the IVD and the mechanics of the entire functional
spinal unit.4,71 With this in mind, a NP replacement should attempt to mimic or
reestablish the native properties of the human NP. Compared to native human NP, the
equilibrium modulus 5.39 ± 2.56kPa26,72, the ABNP falls within range of reported values.
The percent relaxation however for the ABNP tends to be higher than reported values for
human NP due to how hydrated / swollen the ABNP scaffolds become through the
decellularization process due to the increased porosity and GAG loss.
Through DMA testing the viscoelastic properties of the complex, storage, loss
moduli and phase angle could be evaluated. Both ABNP and fresh bovine NPs were
subjected to this unconfined DMA testing and compared to native human NP. The values
for both the complex modulus and phase angle fall within the lower to mid range of
human NP reported values, 7-21kPa and 23-31˚ respectively, over the frequencies tested.
7,9

Therefore, with this data and the biochemical data it is possible that the ABNP can

become a mechanically efficient replacement scaffold that would be aptly able to mimic
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the native human NP at physiologically low strains long enough for cells to remodel and
heal the degenerated IVD.

4.5 In vitro Cell Studies
In conjunction with a decellularized scaffold, a NP tissue replacement would also
require the use of cell sources that are capable to regenerate the NP ECM. Cells are
needed to aid in tissue regeneration since they have been shown to aid in the remodeling
and improvement of both biochemical and viscoelastic properties of the tissue.69,73–78 The
use of autologous NP cells is not feasible for several reasons including, obtaining low
yields of cells from harvest and damaging the disc causing more degeneration.
Furthermore, NP cells harvested from degenerated discs exhibit altered phenotypes with
reduced capacity for matrix synthesis and therefor should not be considered as a cell
source.79 Stem cells are commonly used as an alternative source of healthy cells for tissue
engineering applications. The use of human amniotic mesenchymal stem cells (hAMSCs)
were chosen due to their high availably, as compared to bone marrow and adipose
derived stem cells, and multipotent charecteristics.73,76,80 Furthermore, literature suggests
biomimetic NP scaffolds may promote stem cell differentiation in the absence of
exogenous cues.51,52

4.6 In vitro Cell Injection Studies
Prior to this study we were able to demonstrate greater than 95% stem cell
viability when seeding on the surface of the ABNP illustrating it’s cytocompatibility,
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however cell penetration was not observed over the 14-day period. Therefore, we injected
hAMSCs via a 28G syringe into the center of the ABNP scaffolds. Additionally a group
of ABNP scaffolds were cross-linked using EDC/NHS fixation in order to cross-link
GAGs to the collagen as a way to prevent scaffold destruction when implanted into a
destructive environment as is commonly observed in the degenerating IVD.16,17,81–83
From initial studies it is observable that cells were able to survive within the center of
both the scaffolds however, viability was significantly higher in non-crosslinked
scaffolds. This could be due to scaffolds not thoroughly being rinsed of crosslinking
solution and will need to be optimized in future studies as well as assessing the effect
of crosslinking on mechanical properties of cell seeded and non-seeded scaffolds.
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CHAPTER FIVE
CONCLUSIONS & RECOMMENDATIONS FOR FUTURE STUDIES
5.1 Conclusion:
Over the past decade, numerous advances in IDD treatments have been made in
order to understand and address the causes of degeneration instead of treating the
symptoms. However, current research has unable to create a scaffold that mimics both the
biochemical and mechanical properties of NP. Groups have therefore been using
decellularization to retain the native ECM and then seed cells onto these scaffolds to
improve the native properties with limited success. Current problems with this technique
are being able to maintain enough native ECM while also removing as much xenogeneic
properties as possible.43,53,69 Results from the studies carried out within this publication
have demonstrated the ability to fully decellularize the bovine NP. Our results suggest
that an optimal decellularization procedure utilizes a combination of both physical and
chemical methods. With this method it was possible to preserve the native NP ECM
while also removing any significant xenogeneic material. Biochemical components and
viscoelastic properties of the ABNP scaffold alone were similar to values of native
human NP. Additionally the ABNP scaffold demonstrated excellent cytocompatibility
with human stem cells further confirming its utility as a scaffold material for human NP
tissue engineering.

67

5.2 Recommendations for Future Work
The next logical step for future studies would be to both optimize and
characterize, both biochemically and mechanically, the EDC: NHS cross-linked ABNP
scaffolds as well as characterize both the stem cell seeded ABNP and cross-linked ABNP
scaffolds. Following mechanical testing analysis, investigators will be able to determine
how the crosslinking affects the mechanical properties of the cross-linked ABNP
scaffolds. Stem cell characterization, in order to observe any differentiation into NP-like
or notochordal-like cells, would aid investigators to better understand both the effects of a
decellularized scaffold on cells as well as how well the scaffolds are able to provide cue
for differentiation on stem cells. Additionally, a study utilizing factors associated with
IDD to perform an accelerated degeneration model to observe how well both the ABNP
and cross-linked ABNP scaffolds last in a degenerated environment. Further
investigations, after additional scaffold characterization, would be to perform a large
animal model to observe how scaffolds perform in vivo. The use of an animal with a large
disc space and mechanically similar properties would be ideal in order to better observe
clinically relevant results.
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